Nativis Enters into Exclusive Licensing Agreement for Glioblastoma Multiforme in Japan
04 Avril 2017 - 02:00PM
Business Wire
Nativis, Inc. (Nativis), a clinical-stage life science
bio-electronic company developing non-invasive, safe and highly
effective treatments for cancers and other serious diseases, today
announced that the company has entered into an exclusive licensing
agreement for the development and commercialization of Nativis’
proprietary ultra-low Radio Frequency Energy (ulRFE™) technology
for the potential treatment of Glioblastoma Multiforme (GBM) in the
Japanese market, with Teijin Limited (Teijin), a comprehensive
Japanese company expanding businesses in high-performance
materials, pharmaceuticals, home healthcare, product converting and
information technology.
Under the terms of the agreement, Teijin will receive an
exclusive license to the Nativis Voyager® System for the indication
of GBM in Japan. Nativis will receive an undisclosed upfront
payment, payments based on the achievement of specific regulatory
and commercial milestones, and royalties on the sales of the
product in Japan. Teijin will sublicense its rights under the
agreement to Teijin Pharma Limited (Teijin Pharma), Teijin’s
wholly-owned subsidiary and the core company of Teijin Group’s
healthcare business, under which Teijin Pharma will develop and
commercialize the licensed technology in Japan.
Nativis and Teijin also anticipate expansion of the scope of the
alliance and will continue discussions for potential licensing
opportunities of the Nativis ulRFE™ technology for other
indications in Japan.
“We are very pleased to enter into this exclusive licensing
agreement with Teijin for GBM; the company has a strong track
record of successfully commercializing pharmaceuticals and medical
devices in Japan. We believe that this partnership further
validates our technology, while their investment in Nativis
reinforces our belief in the broader potential of the Voyager
platform. With their support, we look forward to further developing
and refining the Voyager System for GBM, as well as additional
indications in the future,” commented Chris Rivera, President and
Chief Executive Officer of Nativis. “This agreement also brings us
one step closer to reaching our goal of becoming cash flow positive
through strategic partnerships and licenses, and we are excited to
work closely with Teijin to bring the Voyager System to market in
Japan.”
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering
advanced solutions in the areas of environmental value; safety,
security and disaster mitigation; and demographic change and
increased health consciousness. Its main fields of operation are
high-performance fibers such as aramid, carbon fibers &
composites, healthcare, films, resin & plastic processing,
polyester fibers, products converting and IT. The group has some
150 companies and around 19,000 employees spread out over 20
countries worldwide. It posted consolidated sales of JPY 790.7
billion (USD 7.4 billion) and total assets of JPY 823.4 billion
(USD 7.7 billion) in the fiscal year ending March 31, 2016.
About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a
clinical-stage bio-electronics company. Nativis has invented and
patented a groundbreaking technology that utilizes precisely
targeted, ultra-low radio frequency energy (ulRFE) to specifically
regulate metabolic pathways on the molecular and genetic levels –
without chemicals, radiation or drugs – delivered via a
simple-to-use non-invasive device called Nativis Voyager®. The
company’s goal is to transform disease treatment on a global scale
with ulRFE that can potentially be applied to a wide range of
conditions and other human health-related needs (together with
other applications including agriculture, bio-fuels and veterinary
medicine, to name a few). Nativis’ initial focus is on the
treatment of patients with brain cancer (initially, recurrent
glioblastoma), who are not well served by conventional standard of
care therapies, which often result in poor outcomes and devastating
side effects. Additional pre-clinical work is being completed for
melanoma, lung cancer, liver cancer, inflammatory disease and
chronic pain.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170404005328/en/
NativisDennis Kroft, 206-708-2288dkroft@nativis.com